Product Name

Obeticholic Acid

CAS Number

459789-99-2

LGM Pharma is an API distributor. LGM Pharma can supply CGMP and/or DMF products, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, pharmacies, or any pharmaceutical companies.

Questions? Call our customer API support number 1-(800)-881-8210

Product Name:
Obeticholic Acid
CAS Number:
459789-99-2
Indication:
Obeticholic Acid is indicated as a primary farnesoid X receptor agonist to treat chronic liver diseases, particularly Primary Biliary Cirrhosis. Other indications for Obeticholic Acid therapy include Primary Sclerosing Cholangitis and Bile Acid Diarrhea. Intercept Pharmaceuticals has attained orphan drug designation for Obeticholic Acid therapy in the United States and Europe for the treatment of Primary Biliary Cirrhosis.
Mode of Action:

Obeticholic Acid’s mechanism of action is unique as it acts as a hepatoprotective agent against a wide range of chronic liver diseases.

Pharmacodynamics:

Obeticholic Acid is a semi-synthetic derivative of bile acid and works by adhering to a receptor in the liver, thus changing the metabolism of lipids in the body. As a natural agonist of the farnesoid X receptor, Obeticholic Acid acts as a nuclear hormone receptor which regulates lipid metabolism and glucose, thus decreasing hepatic steatosis and insulin resistance.

Metabolism:

Obeticholic Acid In vitro acts as a powerful farnesoid X receptor agonist in HuH7 cells. In vivo Obeticholic Acid protects against acute necrosis, protects hepatocytes, reduces renal inflammation and oxidative stress and improves proteinuria.  

Toxicity:

Obeticholic Acid has not shown toxicity and the main adverse effect noted by patients is mild itching.

IUPAC:
Cholan-24-oic acid, 6-ethyl-3, 7-dihydroxy-, (3alpha, 5beta, 6alpha, 7alpha)-
Formula:
C26H44O4
Synonyms:
6-ECDCA, 6-Ethylchenodeoxycholic acid, 6alpha-Ethyl-chenodeoxycholic acid, INT 747, INT-747, INT747, Obeticholic acid, UNII-0462Z4S4OZ
SMILES:
CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCC(=O)O)C)C)O
InChi:
1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1
General Reference:
General Reference:
  1. Gastroenterology. 2013 Sep;145(3):574-82.e1. doi: 10.1053/j.gastro.2013.05.042. Epub 2013 May 30.
  2. European Association for the Study of the Liver (EASL) International Liver Congress 2014

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.

Questions? Call our customer API support number 1-(800)-881-8210. 

Ask us about this product

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants
  • Technical packages as well as access to filed DMF, ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any submission type based on specific customer requirements

Find an API Product

SEARCH
Generic filters